Management Commentary

Stallion India Fluorochemicals Targets Strong Multi-Year Growth Amid R-32 Expansion and Specialty Gas Push

NSE

STALLION

BSE

544342

Stallion India Fluorochemicals shared its Q4 FY26 investor conference transcript highlighting 14.4% YoY revenue growth, 35.6% PAT growth, upcoming R-32 manufacturing expansion, semiconductor gas opportunities, and a long-term roadmap targeting ₹3,000 crore revenue and ₹500 crore PAT by 2030.

PRICE-SENSITIVE TRIGGER

Event: Release of investor conference transcript for Q4 and FY26 earnings call

Type: Management Commentary and Strategic Business Update

Impact: Positive

Immediate Effect: Management reiterated aggressive growth guidance supported by the Bhilwara R-32 project, specialty gas expansion, helium infrastructure, and future HFO manufacturing plans, strengthening long-term growth visibility.

Key Metrics:

FY26 Revenue:
- ₹434.12 crore
- YoY growth: 14.4%
FY26 EBITDA:
- ₹61.35 crore
- YoY growth: 23.34%
FY26 PAT:
- ₹43.84 crore
- YoY growth: 35.61%
FY26 PAT target achieved:
- Management earlier guided for ₹430 crore revenue and ₹40 crore PAT
- Actual performance exceeded guidance
FY27 management outlook:
- Revenue target implied above ₹560 crore
- PAT guidance around ₹100 crore
Long-term target by 2030:
- Revenue target: ₹3,000 crore
- PAT target: ₹500 crore

Highlight:

Management expects R-32 manufacturing operations to materially improve margins, with projected PAT margins of 22%-24% from manufacturing operations.

What Happened ?

Stallion India Fluorochemicals released the transcript of its Q4 FY26 investor conference call, where management discussed financial performance, upcoming manufacturing projects, specialty gas expansion, and long-term strategic plans.

The company reported strong FY26 operational performance despite geopolitical disruptions, supply chain volatility, and fluctuations in global energy markets. Management highlighted that environmental clearance has already been received for the proposed 10,000 metric ton R-32 manufacturing facility at Bhilwara, Rajasthan, with production expected by October 2026.

The company also outlined expansion plans in helium handling, semiconductor gases, HFO blending, and specialty fluorochemicals through facilities at Mumbattu and Khalapur. Management reiterated confidence in achieving 30%-35% revenue CAGR over the next three years through backward integration and specialty product expansion.

Key Details

Strategic Expansion, Manufacturing Roadmap
and Specialty Gas Growth:

Bhilwara R-32 manufacturing facility:
- Capacity: 10,000 metric tons
- Environmental clearance received
- Expected commissioning: October 2026
Strategic objective of R-32 project:
- Backward integration
- Margin expansion
- Import substitution opportunity
Management expects:
- ₹250 crore revenue contribution from R-32 operations in FY27 if commissioning occurs on schedule
Upcoming Mumbattu facility:
- South India expansion
- HFO and HFC refrigerant blending
- Semiconductor gas handling
- Helium infrastructure
Khalapur expansion:
- Liquid helium and semiconductor gas infrastructure scaling
Specialty gases focus sectors:
- Semiconductors
- Electronics
- Healthcare
- Solar
- Advanced manufacturing
Long-term growth guidance:
- 30%-35% CAGR over next three years
- Margin improvement guidance of 3%-4%
Future HFO manufacturing plans:
- Estimated total capex around ₹400 crore
- Project expected post stabilization of R-32 operations
Semiconductor business outlook:
- Management views semiconductor gases as a major long-term growth driver
- Qualification cycles expected to take multiple years
Helium business:
- Khalapur helium plant expected operational shortly
- Geopolitical disruptions have increased helium pricing substantially

Note:

Management stated that the company prefers phased expansion with operational stabilization before executing the next major capex cycle.

Risk Analysis

Summary:

Execution timing, global fluorochemical pricing volatility, geopolitical disruptions, quota allocation mechanisms, and specialty gas commercialization remain key business risks despite strong growth visibility.

Key Risks:

Delay in Bhilwara commissioning could impact FY27 revenue targets.
R-32 quota allocation remains subject to government policy decisions.
Semiconductor gas commercialization requires long qualification timelines.
Global geopolitical instability continues to impact supply chains and logistics.
Fluorochemical pricing remains cyclical and commodity-sensitive.
High future capex commitments may increase operational execution risk.
Specialty gas expansion requires technical capability scaling and customer validation.

Worst Case Scenario:

If R-32 commissioning gets delayed materially or quota allocations fall below expectations, projected FY27 profitability and medium-term growth targets may weaken significantly.

Risk Level: Medium

Company Commentary

Management reiterated confidence in achieving 30%-35% growth over the next three years.
The Bhilwara R-32 project is progressing as planned.
The company expects meaningful contribution from specialty gases and semiconductor opportunities over the long term.
Management stated that the company is targeting ₹3,000 crore revenue and ₹500 crore PAT by 2030.
Stallion expects manufacturing-led margin expansion after backward integration.
The company highlighted that it remains conservatively financed and operationally disciplined during expansion.

Official Exchange Filing: Stallion India Fluorochemicals Limited